Literature DB >> 25926120

Association of primary hyperparathyroidism and humoral hypercalcemia of malignancy in a patient with clear cell renal carcinoma.

Letícia da Silva Gomes1, Carolina A M Kulak1, Tatiana Munhoz da Rocha Lemos Costa1, Evandro Cezar Guerreiro Vasconcelos1, Maurício de Carvalho1, Victoria Zeghbi Cochenski Borba1.   

Abstract

Hypercalcemia is found frequently in patients with cancer. Besides the etiology related to the malignancy, other causes should be considered in the differential diagnostic, as primary hyperparathyroidism, granulomatous diseases and the use of thiazide diuretics. We present a case report of a severe hypercalcemia due to a rare association and review the relevant literature. A female patient, 57 years old, sent to the Endocrinology Service of Hospital das Clínicas da Universidade do Paraná (SEMPR) in order to investigate severe hypercalcemia with frequent need of hospitalization. The patient was in chemotherapy treatment for recurrence of clear cell renal cancer. During the investigation she presented high level of parathyroid hormone (PTH) and parathyroid scintigraphy suggestive of hyperplasia/ adenoma of parathyroid, histopathological diagnosis was confirmed after parathyroidectomy. After surgery the patient presented undetectable levels of PTH. However, she continued with progressive increase of serum calcium, with no signs of bone metastases or change in vitamin D metabolism. The investigation showed high levels of PTH-related protein (PTHrP), leading us to the diagnosis of hypercalcemia of malignancy. The patient presented severe hypercalcemia due to the rare association of primary hyperparathyroidism and humoral hypercalcemia of malignancy due to secretion of PTHrP by tumor cells. The presence of isolated primary hyperparathyroidism, as a cause of hypercalcemia in cancer patients, has been described in approximately 5-10% of the patients. However, the association of primary hyperparathyroidism and humoral hypercalcemia of malignancy (which means with concomitant elevation of PTH and PTHrP) is rare, only three cases have been described in the literature.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25926120     DOI: 10.1590/2359-3997000000015

Source DB:  PubMed          Journal:  Arch Endocrinol Metab        ISSN: 2359-3997            Impact factor:   2.309


  4 in total

1.  Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.

Authors:  Tariq Chukir; Yi Liu; Katherine Hoffman; John P Bilezikian; Azeez Farooki
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

2.  Ovarian cancer presenting with hypercalcemia: two cases with similar manifestations but different mechanisms.

Authors:  Xuegong Ma; Yingmei Wang; Xuhong Zhang; Mengting Dong; Wen Yang; Fengxia Xue
Journal:  Cancer Biol Med       Date:  2018-05       Impact factor: 4.248

3.  Hypercalcemia of Malignancy Attributed to Cosecretion of PTH and PTHRP in Lung Adenocarcinoma.

Authors:  Jeffrey M Kroopnick; Ubaldo Martinez-Outschoorn; Madalina Tuluc; Caroline S Kim
Journal:  AACE Clin Case Rep       Date:  2021-01-19

4.  Pazopanib as salvage therapy in metastatic renal cell carcinoma with hypercalcemic crisis and renal insufficiency: a case report and literature review.

Authors:  Ying Chen; Xiaoming Ling; Wencui Kong; Shuiliang Wang; Zongyang Yu
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.